Concepedia

Author

Elizabeth Ditty

Mersana Therapeutics (United States)ORCID

Also Known As

Elizabeth Ditty

49

Publications

122

Citations

6

H-Index

27

Concepts

All Affiliations

Mersana Therapeutics (United States)
ED

About

Elizabeth Ditty is an author at Mersana Therapeutics (United States) specializing in medicine, immunotherapy, and radiation oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

4

4

91

2

Immunology

3

3

80

3

Engineering

1

1

33

4

Biomolecular Engineering

1

1

33

5

Cell Biology

1

1

11

Elizabeth Ditty

×

5

Publications

111

Citations

5

H-Index

YearCitations

Discovery and Preclinical Characterization of XMT-1660, an Optimized B7-H4-Targeted Antibody–Drug Conjugate for the Treatment of Cancer

Dorin Toader, Shawn P. Fessler, Scott D. Collins,

Molecular Cancer Therapeutics

2023

33

Abstract 3503: XMT-2056, a HER2-targeted Immunosynthen STING-agonist antibody-drug conjugate, binds a novel epitope of HER2 and shows increased anti-tumor activity in combination with trastuzumab and pertuzumab

Jeremy R. Duvall, Raghida A. Bukhalid, Naniye Mallı Cetinbas,

Cancer Research

2022

24

Abstract 1738: XMT-2056, a well-tolerated, Immunosynthen-based STING-agonist antibody-drug conjugate which induces anti-tumor immune activity

Jeremy R. Duvall, Raghida A. Bukhalid, Naniye Mallı Cetinbas,

Cancer Research

2021

23

XMT-2056, a HER2-Directed STING Agonist Antibody–Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune Cells

Raghida A. Bukhalid, Jeremy R. Duvall, Kelly L. Lancaster,

Clinical Cancer Research

2025

20

Abstract 2894: XMT-1592, a site-specific Dolasynthen-based NaPi2b-targeted antibody-drug conjugate for the treatment of ovarian cancer and lung adenocarcinoma

Shawn P. Fessler, Anouk Dirksen, Scott D. Collins,

Cancer Research

2020

11

Page 1